Cash alongside earnings
Kenvue’s nine-month free cash flow increased from $1.0 billion to $1.6 billion, while the consumer health company’s third-quarter sales grew 3.2%. Cash generation improved faster than the quarterly sales growth rate, but those figures cover different periods. I therefore avoid dividing quarterly sales into nine-month cash flow to manufacture an efficiency ratio. The more useful calculation starts with operating cash, investment and working capital over the same nine months.[1]
Operating cash increased from $1.3 billion to $1.9 billion over the first nine months, while capital expenditure fell from $0.4 billion to $0.3 billion. Higher operating cash and lower investment spending both supported free cash flow. The amounts are rounded, so adding their changes to assign precise contribution shares would be misleading. Their direction still matters: the improvement extends beyond lower investment payments, with operations also providing more cash.[1]
The room created by working capital
Management attributes stronger operating cash to higher net income and lower working capital usage. Working capital connects cash tied up in inventories and receivables with short-term operating liabilities. A smaller cash requirement can improve cash flow even without equally rapid sales growth. Kenvue does not quantify those two contributors separately here. Assigning the entire cash increase to a lasting improvement in earnings power would therefore go beyond the disclosed breakdown.[1]
Lower working capital usage could reflect a durable operating improvement or the timing of collections and payments between periods. Those alternatives have different implications for shareholders. Supporting the same sales with less cash tied up creates operating room; a temporary timing benefit shifts cash between periods. I regard the $1.6 billion of free cash flow as a strong realized result while leaving its automatic recurrence outside the conclusion.[1]
What supports the margin improvement
The quarter also contained tangible operating progress. Organic sales growth of 2.9% comprised 1.6% from volume and 1.3% from price and mix. Operating margin increased from 16.7% to 18.2%, while the adjusted margin rose from 21.5% to 21.9%. Improvement in both measures supports an operating gain beyond adjustments alone. The company nevertheless includes tariff refunds alongside productivity and supply chain savings among the contributors, and those sources have different prospects for recurrence.[1]
For shareholders, the assessment turns on how much sales convert into cash and what sustains that conversion. Kenvue ended the period with $1.0 billion in cash and $8.2 billion of debt, compared with debt of $8.5 billion at the preceding fiscal year end. Stronger cash generation provides room to reduce debt, although concurrent changes do not identify the funding source of a particular payment. My focus in subsequent results is the working capital contribution and persistence of margin savings. Sales growth, cash conversion and the debt burden then become parts of the same capital allocation calculation.[1]